<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160307026950N85</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-08-01</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Preventive Strategies for Postoperative Sore Throat</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the Effectiveness of Ginger Tea Gargling with Ketamine Gargling in Preventing Postoperative Sore Throat in Patients Under General Anesthesia with Endotracheal Intubation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>15</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/92020</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Other design features: This study is designed as a prospective, randomized, controlled, double-blind, three-arm parallel clinical trial. Participants will be randomly allocated to three parallel groups using block randomization with a block size of six: ginger tea gargle, ketamine gargle, and control groups. To maintain blinding, all solutions will be prepared by the hospital pharmacist in identical, coded bottles. Participants and outcome assessors (recovery room nurses or interns) will be blinded to group allocation. The incidence and severity of postoperative sore throat following endotracheal intubation will be assessed at predefined time points and compared among the groups, Randomization description: The random allocation sequence will be generated using block randomization with a fixed block size of 6, with an allocation ratio of 1:1:1 to the ginger, ketamine, and control groups. The randomization sequence will be generated using the online Sealed Envelope Randomization Service. The generated sequence will be used sequentially for participant allocation. The randomization list will be prepared and maintained by an individual independent of the outcome assessors, and group allocation will remain concealed from the patients and outcome assessors until completion of the intervention and outcome assessment, Blinding description: This study will be conducted using a double-blind design. Participants will be blinded to the type of intervention received (ginger tea gargle, ketamine gargle, or control solution). All solutions will be prepared by the hospital pharmacist in identical, coded bottles to ensure that the interventions are indistinguishable.

Outcome assessors (recovery room nurses or interns) responsible for evaluating postoperative sore throat will be blinded to group allocation. Healthcare personnel involved in routine postoperative care will remain unaware of treatment allocation whenever they do not require access to the randomization codes.

The principal investigator and research team members involved in data collection and analysis will not have access to the allocation codes until completion of data collection and initial analyses. The randomization codes will be revealed only after completion of the planned analyses.

Data analysts will analyze coded data without knowledge of intervention assignments whenever feasible. Members of the Data Safety Monitoring Committee (if applicable) and individuals involved in manuscript preparation will remain blinded to group allocation unless access to this information is required.</study_design>
      <phase>3</phase>
      <hc_freetext>sore throat.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Receiving ginger tea gargle solution according to the study protocol before surgery; the solution is prepared in identical coded bottles and administered by gargling. Intervention 2: Intervention group: Receiving ketamine gargle solution according to the study protocol before surgery; the solution is prepared in identical coded bottles and administered by gargling. Intervention 3: Control group: Receiving a control solution (placebo) similar to the intervention solutions, without the active ingredient, prepared in identical coded bottles; administered according to the study protocol before surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The main outcome information will be shared after being de-identified

When:
Access period begins 6 months after results are published

To whom:
Employees in public and private scientific institutions

Conditions:
Analysis on the data is not allowed

Where to obtain:
Behzad Nazim Al-Raaya with email behzad_nazem@med.mui.ac.ir

How to obtain:
Immediately upon request

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Behzad Nazemroaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezarjirib st,  Isfahan,  Iran</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3212 3543</telephone>
        <email>behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behzad Nazemroaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezarjirib st,  Isfahan,  Iran</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3212 3543</telephone>
        <email>behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Written informed consent obtained
absence of underlying throat-related conditions (e.g., severe gastroesophageal reflux disease [GERD] or respiratory tract infection)
Patients with American Society of Anesthesiologists (ASA) physical status I–II
Patients undergoing elective surgical procedures (e.g., cholecystectomy, hernia repair, or thyroidectomy) requiring endotracheal intubation for a duration exceeding 30 minutes</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to ginger or ketamine
emergency surgery
body mass index (BMI) &gt;35 kg/m²
surgery lasting more than 3 hours</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R07.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pain in throat</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Receiving ginger tea gargle solution according to the study protocol before surgery; the solution is prepared in identical coded bottles and administered by gargling.</i_keyword>
      <i_keyword>Intervention group: Receiving ketamine gargle solution according to the study protocol before surgery; the solution is prepared in identical coded bottles and administered by gargling.</i_keyword>
      <i_keyword>Control group: Receiving a control solution (placebo) similar to the intervention solutions, without the active ingredient, prepared in identical coded bottles; administered according to the study protocol before surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of postoperative sore throat (POST) following endotracheal intubation, measured using the visual analog scale (VAS: 0–10). Timepoint: Assessment of postoperative sore throat (POST) severity using the visual analog scale (VAS: 0–10) at 2, 6, and 24 hours after surgery. Method of measurement: Visual Analogue Scale for assessment of postoperative sore throat severity, consisting of a 10-centimeter line scored from zero (no sore throat) to 10 (the worst imaginable sore throat).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-07-08</approval_date>
        <contact_name>Research Ethics Committees of School of Medicine - Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences, Hezar Jarib street, Azadi square, Isfahan Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
